OKUR
OnKure Therapeutics, Inc. NASDAQ$4.60
Mkt Cap $62.9M
52w Low $1.70
78.8% of range
52w High $5.38
50d MA $4.01
200d MA $3.07
P/E (TTM)
-1.1x
EV/EBITDA
0.3x
P/B
1.1x
Debt/Equity
0.0x
ROE
-105.9%
P/FCF
-0.8x
RSI (14)
—
ATR (14)
—
Beta
0.15
50d MA
$4.01
200d MA
$3.07
Avg Volume
294.7K
About
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -1.15 | -0.99 | +13.9% | 3.52 | +6.2% | +7.4% | +10.8% | +14.2% | +13.9% | +24.4% | — |
| Nov 6, 2025 | AMC | -1.20 | -1.09 | +9.2% | 3.16 | -2.5% | -7.0% | -2.8% | +0.3% | -2.5% | -0.6% | — |
| Aug 12, 2025 | AMC | -1.23 | -1.14 | +7.3% | 2.00 | +9.5% | +20.0% | +33.5% | +26.5% | +40.0% | +37.0% | — |
| May 6, 2025 | AMC | -1.32 | -1.19 | +9.8% | 2.23 | +0.9% | -3.6% | -10.3% | -13.9% | -12.6% | -17.5% | — |
| Mar 10, 2025 | AMC | -0.86 | -1.37 | -59.3% | 4.96 | +5.8% | -0.2% | -3.4% | -6.9% | -7.1% | -2.8% | — |
| Nov 7, 2024 | AMC | -0.97 | -1.10 | -13.4% | 17.19 | -1.1% | +2.3% | +2.1% | +0.6% | -1.8% | -1.7% | — |
| Aug 13, 2024 | AMC | -1.00 | -1.60 | -60.0% | 13.80 | -4.3% | +6.5% | +13.0% | +12.3% | +14.5% | +14.5% | — |
| May 7, 2024 | AMC | -0.37 | -0.25 | +32.4% | 17.40 | +0.6% | +5.2% | +6.9% | +4.0% | -8.6% | -6.9% | — |
| Dec 31, 2023 | AMC | -5.78 | -7.00 | -21.1% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | -5.71 | -1.44 | +74.8% | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.78 | $3.86 | +2.1% | +3.2% | +6.3% | +6.1% | +15.9% | +10.8% |
| Aug 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.82 | $2.76 | -2.1% | -2.5% | -0.7% | -0.4% | -2.5% | -1.8% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.82 | $4.91 | +1.9% | +1.9% | +3.7% | +3.7% | +4.8% | +2.9% |
| Mar 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.96 | $5.25 | +5.8% | -0.2% | -3.4% | -6.9% | -7.1% | -2.8% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.19 | $17.00 | -1.1% | +2.3% | +2.1% | +0.6% | -1.8% | -1.7% |
Recent Filings
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
OKUR's equity issuance dilutes existing shareholders' ownership percentages and voting power, likely pressuring the stock price unless the capital raised funds high-return investments or addresses urgent operational needs.
Mar 30
8-K
Unknown — 8-K Filing
Okur Therapeutics' on-track PI3K-alpha pipeline, particularly the PIKture-01 trial for OKI-219, suggests potential future catalyst events that could drive clinical validation and reduce clinical-stage development risk for investors.
Mar 12
Data updated apr 26, 2026 5:13pm
· Source: massive.com